Lakshmi Ravindranath
Overview
Explore the profile of Lakshmi Ravindranath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sardar S, McNair C, Ravindranath L, Chand S, Yuan W, Bogdan D, et al.
Oncogene
. 2024 Sep;
43(43):3197-3213.
PMID: 39266679
Castration resistant prostate cancer (CRPC) remains an incurable disease stage with ineffective treatments options. Here, the androgen receptor (AR) coactivators CBP/p300, which are histone acetyltransferases, were identified as critical mediators...
2.
Sardar S, McNair C, Ravindranath L, Chand S, Yuan W, Bogdan D, et al.
bioRxiv
. 2024 May;
PMID: 38766099
Castration resistant prostate cancer (CRPC) remains an incurable disease stage with ineffective treatments options. Here, the androgen receptor (AR) coactivators CBP/p300, which are histone acetyltransferases, were identified as critical mediators...
3.
Duncan A, Nousome D, Ricks R, Kuo H, Ravindranath L, Dobi A, et al.
Biomedicines
. 2023 May;
11(5).
PMID: 37239075
Growing evidence indicates the involvement of a genetic component in prostate cancer (CaP) susceptibility and clinical severity. Studies have reported the role of germline mutations and single nucleotide polymorphisms (SNPs)...
4.
Kohaar I, Zhang X, Tan S, Nousome D, Babcock K, Ravindranath L, et al.
Nat Commun
. 2022 Mar;
13(1):1361.
PMID: 35292633
In prostate cancer, emerging data highlight the role of DNA damage repair genes (DDRGs) in aggressive forms of the disease. However, DDRG mutations in African American men are not yet...
5.
Kohaar I, Chen Y, Banerjee S, Borbiev T, Kuo H, Ali A, et al.
J Urol
. 2020 Sep;
205(2):420-425.
PMID: 32945736
Purpose: Prostate cancer is predominantly indolent at diagnosis with a small fraction (15% to 25%) representing aggressive subtype (Gleason score 7-10), which is prone to metastatic progression. It is critical...
6.
Kohaar I, Li Q, Chen Y, Ravindranath L, Young D, Ali A, et al.
Oncotarget
. 2020 Apr;
11(15):1321-1333.
PMID: 32341752
Introduction: Oncogenic activation of ERG resulting from gene fusion is a key molecular genetic alteration in prostate cancer (CaP). The frequency of ERG fusion is variable by race; however, there...
7.
Sharad S, Sztupinszki Z, Chen Y, Kuo C, Ravindranath L, Szallasi Z, et al.
Cancers (Basel)
. 2019 Dec;
11(12).
PMID: 31842254
Dysfunctions of androgen/TGF-β signaling play important roles in prostate tumorigenesis. Prostate Transmembrane Protein Androgen Induced 1 () inhibits androgen and TGF-β signaling via a negative feedback loop. The loss of...
8.
Yan W, Jamal M, Tan S, Song Y, Young D, Chen Y, et al.
Oncotarget
. 2019 Nov;
10(60):6466-6483.
PMID: 31741711
Background: As a major cause of morbidity and mortality among men, prostate cancer is a heterogenous disease, with a vast heterogeneity in the biology of the disease and in clinical...
9.
Petrovics G, Price D, Lou H, Chen Y, Garland L, Bass S, et al.
Prostate Cancer Prostatic Dis
. 2018 Dec;
22(3):406-410.
PMID: 30542053
Background: Germline mutations in BRCA2 have been linked to a higher risk of prostate cancer (PCa), and high frequency of BRCA1 and BRCA2 (BRCA1/2) gene alterations was recently reported in...
10.
Mohamed A, Xavier C, Sukumar G, Tan S, Ravindranath L, Seraj N, et al.
Cancer Res
. 2018 May;
78(13):3659-3671.
PMID: 29712692
Oncogenic activation of the ETS-related gene () by recurrent gene fusions (predominantly TMPRSS2-ERG) is one of the most validated and prevalent genomic alterations present in early stages of prostate cancer....